Prophylaxis of Donor-Derived HCV Infection in Cardiothoracic Transplant Recipients with Short-Course DAA Therapy
Purpose: Acceptance of hepatitis C virus (HCV) viremic organs has increased access to cardiothoracic transplant. However, standard 8-12 week HCV treatment courses increase cost and treatment burden to transplant recipients with unknown long-term effects on the allograft. We aimed to prevent transmission of HCV from HCV-viremic donors to uninfected cardiothoracic transplant recipients with a peri-operative short course of direct acting antiviral (DAA).
Source: The Journal of Heart and Lung Transplantation - Category: Transplant Surgery Authors: , S. Aslam Source Type: research
More News: Bone Graft | Cardiology | Heart | Heart Transplant | Hepatitis | Hepatitis C | Lung Transplant | Transplant Surgery | Transplants